Tscan Therapeutics is trading at $0.21, down 10.47% on October 13, 2026, amid broader biotech weakness; no clear company-specific announcement explaining the decline was identified.
- The supplied sector context shows XBI down 2.01% during the session, which may have contributed but does not establish the full reason for Tscan Therapeutics’ larger decline.
- A reported manufacturing assessment collaboration concerns TSC-101, but available coverage does not connect it to the share-price decline.